Alnylam Pharmaceuticals | ALNY - Ebit

Stock Price
459.13
Daily Change
7.13 1.58%
Monthly
5.55%
Yearly
81.36%
Q3 Forecast
448.25

Alnylam Pharmaceuticals reported $4.89M in EBIT for its fiscal quarter ending in June of 2025.



Financials
Stock Price USD
Assets USD 4.57B
Cash and Equivalent USD 1.11B
Cost of Sales USD 142.95M
Current Assets USD 3.64B
Current Liabilities USD 1.3B
Debt USD 1.3B
EBIT USD 4.89M
EBITDA USD 18.83M
Employees 2.23K
EPS Earnings Per Share USD 0.32
Equity Capital and Reserves USD 250.59M
Gross Profit on Sales USD 630.74M
Interest Expense on Debt USD 40.25M
Interest Income USD 27.49M
Loan Capital USD 1.03B
Market Capitalization USD 59.08B
Net Income USD -66.28M
Operating Expenses USD 789.89M
Operating Profit USD -16.2M
Ordinary Share Capital USD 130.98M
Pre-Tax Profit USD -35.36M
Sales Revenues USD 773.69M
Selling and Administration Expenses USD 323.31M
Stock USD 71.69M
Trade Creditors USD 102.39M
Trade Debtors USD 567.11M

Ebit Change Date
Acadia Pharmaceuticals USD 32.37M 13.08M Jun/2025
Agios Pharmaceuticals USD -127056000 20.43M Jun/2025
Alnylam Pharmaceuticals USD 4.89M 13.19M Jun/2025
Amgen USD 2.26B 1.34B Jun/2025
Arrowhead Research USD -165550000 546.75M Jun/2025
BioMarin Pharmaceutical USD 276.89M 52.99M Jun/2025
Incyte USD 310.82M 27.18M Jun/2025
Ionis Pharmaceuticals USD 144.78M 290.78M Jun/2025
Moderna USD -817000000 146M Jun/2025
Neurocrine Biosciences USD 145.6M 121.9M Jun/2025
Novartis USD 4.82B 39M Jun/2025
PTC Therapeutics USD -34858000 1.01B Jun/2025
Regeneron Pharmaceuticals USD 1.52B 608.6M Jun/2025
Sanofi EUR 1.51B 704.8M Jun/2025
Sarepta Therapeutics USD 115.58M 415.96M Jun/2025
Takeda JPY 257.79B 387.52B Jun/2025
Tectonic Therapeutic USD -22332000 8.34M Jun/2025
Ultragenyx Pharmaceutical USD -193567000 50.63M Jun/2025
Vertex Pharmaceuticals USD 1.15B 420.8M Jun/2025
Xencor USD -22832000 16.77M Jun/2025